CDK5 and Miyoshi myopathy: Based on the data that the expression of CDK5 is higher in MM compared to normal organs, a phase I/II trial of dinaciclib as a single agent was conducted in patients with relapsed MM at doses of 30–50 mg/m2, administered on day 1 of a 21-day cycle (Kumar et al., 2015).